Reneo Pharmaceuticals RPHM, a clinical-stage company, announced the failure of the mid-stage pivotal STRIDE study of its investigational candidate, mavodelpar (REN001), to treat primary mitochondrial ...
A look at the shareholders of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are private equity firms with 46 ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Reneo Pharmaceuticals is developing mitochondrial disease therapies, with its lead program being mavodelpar or REN001. Mavodelpar has shown promising results in increasing fatty acid oxidation and ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) and OnKure, Inc. is fair to Reneo ...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (RPHM) (“Reneo”) with privately held OnKure, Inc.
Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results